AgomAb Therapeutics: CEO, CFO and a director all bought — score 69/100

The CEO, CFO and a director of AgomAb Therapeutics each reported open-market buys within the same two-day window. The combined $266,670 is modest, but it spans the whole top of the company.

AgomAb TherapeuticsInsider buyConviction 69/100

In this brief: 3 sections 2 min read

- Knotnerus Tim Jasper (Chief Executive Officer) — 11,000 shares @ $8.58, $94,380, holding up +101.6%
- Epstein David R (Director) — 10,000 shares @ $8.635, $86,350, new position
- Kemula Pierre Thadee Victor (Chief Financial Officer) — 10,000 shares @ $8.594, $85,940, new position
- Seniority (15) and conviction (20) carried the score: both the CEO and the CFO bought, and all three insiders either doubled a holding or started one from zero. Breadth contributed 20 on three distinct filers. Dollar size held it back at 13.8 — $266,670 is a small cluster on a log-scaled 35-point component. No penalties applied: no same-day selling and no excluded rows.
- 2026-10-07 is the date the Form 4s were filed; the purchases were executed 2026-10-05 and 2026-10-06.
- Figures are as reported on each insider's Form 4; prices are reported averages.
- This is a report of what insiders disclosed and how the score was computed. It is not investment advice.

Read full analysis on sec.gov

Useful?